GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Other Gross PPE

Galapagos NV (BSP:G1LP34) Other Gross PPE : R$677 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Other Gross PPE?

Galapagos NV's Other Gross PPE for the quarter that ended in Mar. 2024 was R$677 Mil.

Galapagos NV's quarterly Other Gross PPE declined from Sep. 2023 (R$721 Mil) to Dec. 2023 (R$160 Mil) but then increased from Dec. 2023 (R$160 Mil) to Mar. 2024 (R$677 Mil).

Galapagos NV's annual Other Gross PPE declined from Dec. 2021 (R$625 Mil) to Dec. 2022 (R$258 Mil) and declined from Dec. 2022 (R$258 Mil) to Dec. 2023 (R$160 Mil).


Galapagos NV Other Gross PPE Historical Data

The historical data trend for Galapagos NV's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Other Gross PPE Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 206.23 481.62 624.82 257.94 160.00

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 752.22 708.48 721.06 160.00 676.92

Galapagos NV Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Galapagos NV (BSP:G1LP34) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (BSP:G1LP34) Headlines

No Headlines